Objective To comprehensively describe the epidemiology, clinical outcomes, and treatment modes of post-transplant cytomegalovirus (CMV) infection in solid organ transplant (SOT) recipients in China. Methods Relevant studies were retrieved from domestic and foreign databases from 2013 to 2023. Indicators such as CMV infection incidence were included. Random-effects model analysis was conducted using R software. Results A total of 29 studies were included in the analysis, with an overall CMV infection incidence of 22.51%. CMV infection incidence after liver and kidney transplant were 23.62% and 13.01%, respectively. CMV infection rates after thoracic organ transplant were 52.27% and 61.24%. When serological status of donors and recipients was D+/R-, the incidence of CMV infection in transplant recipients was higher (83.89%). The incidence of CMV disease in CMV infected patients was 46.22%. Ganciclovir and valganciclovir were commonly used agents, but both had high risks of bone marrow suppression. Conclusion In China, CMV infection is a common viral infection after SOT surgery. Agents with better treatment efficacy and tolerance is necessary in clinics.